Notably, the inhibition of NOS has shown to reduce nitric oxide (NO)-mediated NET formation in vitro [117], suggesting that the NOS inhibitor could also be used as a potential therapy in CRC management. The gene discussed is NOS2; the disease is colorectal carcinoma.